Elucidating the Sodium Channel-Targeting Anti-Seizure Medication Interactome: A Drug-Target Pathway Analysis
Epilepsy is a common neurological disorder in both children and adults, primarily managed with anti-seizure medications (ASMs). Sodium channel blockers are among the most commonly used ASMs. These medications exhibit distinct spectra of efficacy and side effect profiles. These likely result from different off-target interactions, protein binding profiles, and subunit selectivity that remain poorly characterized. We developed a neural network-based computational pipeline to systematically elucidate the molecular targets and associated biological pathways of selected sodium channel-modulating ASMs: carbamazepine, lamotrigine, eslicarbazepine, licarbazepine, lacosamide, phenytoin, and cenobamate. Using the DRIFT (Drug-target identification based on chemical similarity) algorithm for proteome-wide target prediction, we identified protein targets for these ASMs. The sodium channel alpha subunit family was the highest-ranked target for every drug except cenobamate, for which it ranked second behind the GABA-A receptor. Pathway mapping in the Reactome database revealed both shared and drug-specific biological processes. Furthermore, molecular docking studies elucidated the atomistic interactions between the drugs and the predicted targets. Specifically, the predicted target landscape varied from eslicarbazepine and licarbazepine (59 predicted targets each) to lacosamide (18). Pathway analysis revealed recurrent enrichment in rapid depolarisation and the interaction between L1 and ankyrins shared across all drugs, alongside predicted off-targets, including the cannabinoid CB1 receptor for phenytoin and the carbonic anhydrases for lacosamide. Molecular docking supported these predictions, with binding scores ranging from -24 to -31 kcal/mol. Overall, this work provides a systems-level view of NaV-targeting ASM pharmacology and a hypothesis-generating framework to prioritize mechanistic and combination studies of these medications in epilepsy.
Authors
- Howard P. Goodkin (ORCID: https://orcid.org/0000-0003-0528-4949)
- Srinivasan Ekambaram (ORCID: https://orcid.org/0000-0003-2323-8364)
- Nikolay V. Dokholyan (ORCID: https://orcid.org/0000-0002-8225-4025)
- Erika Takle Axeen (ORCID: https://orcid.org/0000-0001-9913-1972)
- Jaideep Kapur (ORCID: https://orcid.org/0000-0002-8608-1352)
Institutions
- University of Virginia (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-17
- DOI
- https://doi.org/10.64898/2026.11.13.766542
- Primary Topic
- Computational Drug Discovery Methods
- Type
- preprint
Funders
- National Institutes of Health